149 related articles for article (PubMed ID: 37017812)
1. HER-2 low status in early-stage invasive lobular carcinoma of the breast: associated factors and outcomes in an institutional series.
Rothschild HT; Clelland E; Patterson A; Molina-Vega J; Kaur M; Symmans WF; Schwartz CJ; Chien AJ; Mukhtar RA
Breast Cancer Res Treat; 2023 Jun; 199(2):349-354. PubMed ID: 37017812
[TBL] [Abstract][Full Text] [Related]
2. Specific sites of metastases in invasive lobular carcinoma: a retrospective cohort study of metastatic breast cancer.
Inoue M; Nakagomi H; Nakada H; Furuya K; Ikegame K; Watanabe H; Omata M; Oyama T
Breast Cancer; 2017 Sep; 24(5):667-672. PubMed ID: 28108967
[TBL] [Abstract][Full Text] [Related]
3. Mixed Invasive Ductal and Lobular Carcinoma of the Breast: Prognosis and the Importance of Histologic Grade.
Metzger-Filho O; Ferreira AR; Jeselsohn R; Barry WT; Dillon DA; Brock JE; Vaz-Luis I; Hughes ME; Winer EP; Lin NU
Oncologist; 2019 Jul; 24(7):e441-e449. PubMed ID: 30518616
[TBL] [Abstract][Full Text] [Related]
4. Biomarker profile of invasive lobular carcinoma: pleomorphic versus classic subtypes, clinicopathological characteristics and prognosis analyses.
Zhang Y; Luo X; Chen M; Yang L; Lei T; Pu T; Wei B; Bu H; Zhang Z
Breast Cancer Res Treat; 2022 Jul; 194(2):279-295. PubMed ID: 35666367
[TBL] [Abstract][Full Text] [Related]
5. The prognosis of invasive ductal carcinoma, lobular carcinoma and mixed ductal and lobular carcinoma according to molecular subtypes of the breast.
Zhao H
Breast Cancer; 2021 Jan; 28(1):187-195. PubMed ID: 32812198
[TBL] [Abstract][Full Text] [Related]
6. Relative effectiveness of adjuvant chemotherapy for invasive lobular compared with invasive ductal carcinoma of the breast.
Marmor S; Hui JYC; Huang JL; Kizy S; Beckwith H; Blaes AH; Rueth NM; Tuttle TM
Cancer; 2017 Aug; 123(16):3015-3021. PubMed ID: 28382636
[TBL] [Abstract][Full Text] [Related]
7. Magnitude of trastuzumab benefit in patients with HER2-positive, invasive lobular breast carcinoma: results from the HERA trial.
Metzger-Filho O; Procter M; de Azambuja E; Leyland-Jones B; Gelber RD; Dowsett M; Loi S; Saini KS; Cameron D; Untch M; Smith I; Gianni L; Baselga J; Jackisch C; Bell R; Sotiriou C; Viale G; Piccart-Gebhart M
J Clin Oncol; 2013 Jun; 31(16):1954-60. PubMed ID: 23589556
[TBL] [Abstract][Full Text] [Related]
8. Quantifying hormone receptor status in lobular breast cancer in an institutional series: the relationship between estrogen and progesterone receptor status and outcomes.
Clelland EN; Rothschild HT; Patterson A; Molina-Vega J; Kaur M; Symmans WF; Schwartz CJ; Chien AJ; Benz CC; Mukhtar RA
Breast Cancer Res Treat; 2023 Nov; 202(2):367-375. PubMed ID: 37500962
[TBL] [Abstract][Full Text] [Related]
9. Strong adverse effect of epidermal growth factor receptor 2 overexpression on prognosis of patients with invasive lobular breast cancer: a comparative study with invasive ductal breast cancer in Chinese population.
Wang T; Ma Y; Wang L; Liu H; Chen M; Niu R
Tumour Biol; 2015 Aug; 36(8):6113-24. PubMed ID: 25804795
[TBL] [Abstract][Full Text] [Related]
10. Effect of histological breast cancer subtypes invasive lobular versus non-special type on survival in early intermediate-to-high-risk breast carcinoma: results from the SUCCESS trials.
Dayan D; Lukac S; Rack B; Ebner F; Fink V; Leinert E; Veselinovic K; Schütze S; El Taie Z; Janni W; Friedl TWP
Breast Cancer Res; 2023 Dec; 25(1):153. PubMed ID: 38098086
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the clinicopathological features of invasive ductal, invasive lobular, and mixed (invasive ductal + invasive lobular) carcinoma of the breast.
Zengel B; Yararbas U; Duran A; Uslu A; Elıyatkın N; Demırkıran MA; Cengiz F; Şimşek C; Postacı H; Vardar E; Durusoy R
Breast Cancer; 2015 Jul; 22(4):374-81. PubMed ID: 23925582
[TBL] [Abstract][Full Text] [Related]
12. Evolution of biological features of invasive lobular breast cancer: Comparison between primary tumour and metastases.
Trillo P; Sandoval J; Trapani D; Nicolò E; Zagami P; Giugliano F; Tarantino P; Vivanet G; Ascione L; Friedlaender A; Esposito A; Criscitiello C; Curigliano G
Eur J Cancer; 2023 May; 185():119-130. PubMed ID: 36989828
[TBL] [Abstract][Full Text] [Related]
13. Comparison of clinical outcomes between luminal invasive ductal carcinoma and luminal invasive lobular carcinoma.
Adachi Y; Ishiguro J; Kotani H; Hisada T; Ichikawa M; Gondo N; Yoshimura A; Kondo N; Hattori M; Sawaki M; Fujita T; Kikumori T; Yatabe Y; Kodera Y; Iwata H
BMC Cancer; 2016 Mar; 16():248. PubMed ID: 27015895
[TBL] [Abstract][Full Text] [Related]
14. HER2-Positive Lobular Versus Ductal Carcinoma of the Breast: Pattern of First Recurrence and Molecular Insights.
Da Ros L; Moretti A; Querzoli P; Pedriali M; Lupini L; Bassi C; Carcoforo P; Negrini M; Frassoldati A
Clin Breast Cancer; 2018 Oct; 18(5):e1133-e1139. PubMed ID: 29759595
[TBL] [Abstract][Full Text] [Related]
15. Histologic tumor type as a determinant of survival in hormone receptor-positive, HER2-negative, pT1-3 invasive ductal and lobular breast cancer.
Göker M; Denys H; Hendrix A; De Wever O; Van de Vijver K; Braems G
Breast Cancer Res; 2023 Nov; 25(1):146. PubMed ID: 37993928
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcomes in patients with triple negative or HER2 positive lobular breast cancer: a single institution experience.
Okines A; Irfan T; Asare B; Mohammed K; Osin P; Nerurkar A; Smith IE; Parton M; Ring A; Johnston S; Turner NC
Breast Cancer Res Treat; 2022 Apr; 192(3):563-571. PubMed ID: 35119530
[TBL] [Abstract][Full Text] [Related]
17. HER2-positive invasive lobular carcinoma: a rare breast cancer which may not necessarily require anti-HER2 therapy. A population-based study.
Kada Mohammed S; Billa O; Ladoire S; Jankowski C; Desmoulins I; Poillot ML; Coutant C; Beltjens F; Dabakuyo S; Arnould L
Breast Cancer; 2023 May; 30(3):343-353. PubMed ID: 36715845
[TBL] [Abstract][Full Text] [Related]
18. Management of HR+/HER2+ lobular breast cancer and trends do not mirror better outcomes.
Yaghi M; Bilani N; Dominguez B; Jabbal IS; Rivera C; Bou Zerdan M; Li H; Saravia D; Stone E; Nahleh Z
Breast; 2022 Aug; 64():112-120. PubMed ID: 35640346
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of Single-Agent Chemotherapy for Patients with Advanced Invasive Lobular Carcinoma: A Pooled Analysis from Three Clinical Trials.
Pérez-Garcia J; Cortés J; Metzger Filho O
Oncologist; 2019 Aug; 24(8):1041-1047. PubMed ID: 30578311
[TBL] [Abstract][Full Text] [Related]
20. Invasive ductal carcinoma with lobular features: a comparison study to invasive ductal and invasive lobular carcinomas of the breast.
Arps DP; Healy P; Zhao L; Kleer CG; Pang JC
Breast Cancer Res Treat; 2013 Apr; 138(3):719-26. PubMed ID: 23535842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
